Do the cholesterol-lowering properties of statins affect cancer risk?

Trends in Endocrinology and Metabolism

Volumn 19, Issue 4, 2008, Pages 113-121

  Solomon, Keith R ^a,b   Freeman, Michael R ^a,b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANDROGEN; ANTINEOPLASTIC AGENT; ATORVASTATIN; CANDICIDIN; FILIPIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; ISOPRENOID; MEVINOLIN; NYSTATIN; PLACEBO; PRAVACOL; PRAVASTATIN; SIMVASTATIN;

ARTICLE; CANCER CELL; CANCER RISK; CHEMOPROPHYLAXIS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HYPOTHESIS; INTERVENTION STUDY; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATE HYPERTROPHY; REGULATOR GENE; SIGNAL TRANSDUCTION; SOLID TUMOR;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; DISEASE PROGRESSION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MODELS, BIOLOGICAL; NEOPLASMS; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 42949170875     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2007.12.004     Document Type: Article

References (98)

1. Bocan T.M. Pleiotropic effects of HMG-CoA reductase inhibitors. Curr. Opin. Investig. Drugs 3 (2002) 1312-1317
2. Davidson M.H. Clinical significance of statin pleiotropic effects: hypotheses versus evidence. Circulation 111 (2005) 2280-2281
3. Waldman A., and Kritharides L. The pleiotropic effects of HMG-CoA reductase inhibitors: their role in osteoporosis and dementia. Drugs 63 (2003) 139-152
4. Bassa B.V., et al. Effect of inhibition of cholesterol synthetic pathway on the activation of Ras and MAP kinase in mesangial cells. Biochim. Biophys. Acta 1449 (1999) 137-149
5. Bi X., et al. Inhibition of geranylgeranylation mediates the effects of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors on microglia. J. Biol. Chem. 279 (2004) 48238-48245
6. Blanco-Colio L.M., et al. 3-Hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apoptosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 161 (2002) 17-26
7. Fenton II J.W., et al. Statin drugs and dietary isoprenoids downregulate protein prenylation in signal transduction and are antithrombotic and prothrombolytic agents. Biochemistry (Mosc.) 67 (2002) 85-91
8. Ghittoni R., et al. Simvastatin inhibits T-cell activation by selectively impairing the function of Ras superfamily GTPases. FASEB J. 19 (2005) 605-607
9. Iishi H., et al. ras p21 Isoprenylation inhibition induces flat colon tumors in Wistar rats. Dis. Colon Rectum 43 (2000) 70-75
10. Ohnaka K., et al. Pitavastatin enhanced BMP-2 and osteocalcin expression by inhibition of Rho-associated kinase in human osteoblasts. Biochem. Biophys. Res. Commun. 287 (2001) 337-342
11. Park H.J., et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ. Res. 91 (2002) 143-150
12. Merck. Information for Prescribers (2005), Merck Sharp & Dohme
13. Bellosta S., et al. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 109 (2004) III50-III57
14. Bocan T.M., et al. Hepatic and nonhepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: comparison with selected HMG-CoA reductase inhibitors. Biochim. Biophys. Acta 1123 (1992) 133-144
15. Corsini A., et al. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol. Res. 31 (1995) 9-27
16. Desager J.P., and Horsmans Y. Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors. Clin. Pharmacokinet. 31 (1996) 348-371
17. Duggan D.E., et al. The physiological disposition of lovastatin. Drug Metab. Dispos. 17 (1989) 166-173
18. Germershausen J.I., et al. Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo. Biochem. Biophys. Res. Commun. 158 (1989) 667-675
19. Koga T., et al. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Biochim. Biophys. Acta 1045 (1990) 115-120
20. McTaggart F. Comparative pharmacology of rosuvastatin. Atheroscler. Suppl. 4 (2003) 9-14
21. Parker R.A., et al. Selective inhibition of cholesterol synthesis in liver versus extrahepatic tissues by HMG-CoA reductase inhibitors. J. Lipid Res. 31 (1990) 1271-1282
22. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam. Clin. Pharmacol. 19 (2005) 117-125
23. Sirtori C.R. Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors. Pharmacol. Ther. 60 (1993) 431-459
24. Vaughan C.J., and Gotto Jr. A.M. Update on statins: 2003. Circulation 110 (2004) 886-892
25. Vickers S., et al. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. Drug Metab. Dispos. 18 (1990) 138-145
26. White C.M. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J. Clin. Pharmacol. 42 (2002) 963-970
27. Monetti M., et al. Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice. Pharmacol. Res. 55 (2007) 441-449
28. Ozacmak V.H., et al. Attenuation of contractile dysfunction by atorvastatin after intestinal ischemia reperfusion injury in rats. Eur. J. Pharmacol. 562 (2007) 138-147
29. Hiatt R.A., and Fireman B.H. Serum cholesterol and the incidence of cancer in a large cohort. J. Chronic Dis. 39 (1986) 861-870
30. Knekt P., et al. Serum cholesterol and risk of cancer in a cohort of 39,000 men and women. J. Clin. Epidemiol. 41 (1988) 519-530
31. Kritchevsky S.B., and Kritchevsky D. Serum cholesterol and cancer risk: an epidemiologic perspective. Annu. Rev. Nutr. 12 (1992) 391-416
32. Freeman M.R., and Solomon K.R. Cholesterol and prostate cancer. J. Cell. Biochem. 91 (2004) 54-69
33. Swyer G.I. The cholesterol content of normal and enlarged prostates. Cancer Res. 2 (1942) 372-375
34. Gordon H.W., and Schaffner C.P. The effect of polyene macrolides on the prostate gland and canine prostatic hyperplasia. Proc. Natl. Acad. Sci. U. S. A. 60 (1968) 1201-1208
35. Keshin J.G. Effect of candicidin on the human benign hypertrophied prostate gland. Int. Surg. 58 (1973) 116-122
36. Klijucharev B.V., et al. Therapeutic action of levorin in adenoma of the prostate. Urol. Nefrol. (Mosk.) 38 (1973) 40-43
37. Orkin L.A. Efficacy of candicidin in benign prostatic hyperplasia. Urology 4 (1974) 80-84
38. Schaffner C.P. Prostatic cholesterol metabolism: regulation and alteration. Prog. Clin. Biol. Res. 75A (1981) 279-324
39. Wang G.M., and Schaffner C.P. Effect of candicidin and colestipol on the testes and prostate glands of BIO 87.20 hamsters. Invest. Urol. 14 (1976) 66-71
40. Schaffner C.P., and Gordon H.W. The hypocholesterolemic activity of orally administered polyene macrolides. Proc. Natl. Acad. Sci. U. S. A. 61 (1968) 36-41
41. Charbonneau C., et al. The interactions of amphotericin B with various sterols in relation to its possible use in anticancer therapy. Biophys. Chem. 91 (2001) 125-133
42. Sporer A., et al. Candicidin: physiologic effect on prostate. Urology 6 (1975) 298-304
43. Swinnen J.V., et al. Androgens markedly stimulate the accumulation of neutral lipids in the human prostatic adenocarcinoma cell line LNCaP. Endocrinology 137 (1996) 4468-4474
44. Heemers H., et al. Androgens stimulate lipogenic gene expression in prostate cancer cells by activation of the sterol regulatory element-binding protein cleavage activating protein/sterol regulatory element-binding protein pathway. Mol. Endocrinol. 15 (2001) 1817-1828
45. Heemers H., et al. Androgens stimulate coordinated lipogenic gene expression in normal target tissues in vivo. Mol. Cell. Endocrinol. 205 (2003) 21-31
46. Swinnen J.V., et al. Androgens, lipogenesis and prostate cancer. J. Steroid Biochem. Mol. Biol. 92 (2004) 273-279
47. Nelson P.S., et al. The program of androgen-responsive genes in neoplastic prostate epithelium. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 11890-11895
48. Eberle D., et al. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie 86 (2004) 839-848
49. Horton J.D., et al. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 12027-12032
50. Ettinger S.L., et al. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res. 64 (2004) 2212-2221
51. Chen Y., and Hughes-Fulford M. Human prostate cancer cells lack feedback regulation of low-density lipoprotein receptor and its regulator, SREBP2. Int. J. Cancer 91 (2001) 41-45
52. Porstmann T., et al. PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene 24 (2005) 6465-6481
53. Cairns P., et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res. 57 (1997) 4997-5000
54. Davies M.A., et al. Regulation of Akt/PKB activity, cellular growth, and apoptosis in prostate carcinoma cells by MMAC/PTEN. Cancer Res. 59 (1999) 2551-2556
55. Lin J., et al. The phosphatidylinositol 3′-kinase pathway is a dominant growth factor- activated cell survival pathway in LNCaP human prostate carcinoma cells. Cancer Res. 59 (1999) 2891-2897
56. Sun M., et al. AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am. J. Pathol. 159 (2001) 431-437
57. Dale K.M., et al. Statins and cancer risk: a meta-analysis. JAMA 295 (2006) 74-80
58. Baigent C., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
59. Browning D.R., and Martin R.M. Statins and risk of cancer: a systematic review and metaanalysis. Int. J. Cancer 120 (2007) 833-843
60. Freeman M.R., et al. Statins and the risk of cancer. JAMA 295 (2006) 2720-2721
61. Giovannucci E., et al. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int. J. Cancer 121 (2007) 1571-1578
62. Sever P.S., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
63. (2002) Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 288, 2998-3007
64. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
65. Coogan P.F., et al. Statin use and the risk of breast and prostate cancer. Epidemiology 13 (2002) 262-267
66. Friis S., et al. Cancer risk among statin users: a population-based cohort study. Int. J. Cancer 114 (2005) 643-647
67. Graaf M.R., et al. The risk of cancer in users of statins. J. Clin. Oncol. 22 (2004) 2388-2394
68. Platz E.A., et al. Statin drugs and risk of advanced prostate cancer. J. Natl. Cancer Inst. 98 (2006) 1819-1825
69. Flick E.D., et al. Statin use and risk of prostate cancer in the California Men's Health Study Cohort. Cancer Epidemiol. Biomarkers Prev. 16 (2007) 2218-2225
70. Jacobs E.J., et al. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol. Biomarkers Prev. 16 (2007) 2213-2217
71. Murtola T.J., et al. Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol. Biomarkers Prev. 16 (2007) 2226-2232
72. Li L., et al. Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol. Cell. Biol. 23 (2003) 9389-9404
73. Mouraviev V., et al. The role of caveolin-1 in androgen insensitive prostate cancer. J. Urol. 168 (2002) 1589-1596
74. Yang G., et al. Elevated expression of caveolin is associated with prostate and breast cancer. Clin. Cancer Res. 4 (1998) 1873-1880
75. Yang G., et al. Combined c-Myc and caveolin-1 expression in human prostate carcinoma predicts prostate carcinoma progression. Cancer 103 (2005) 1186-1194
76. Kurzchalia T.V., and Parton R.G. Membrane microdomains and caveolae. Curr. Opin. Cell Biol. 11 (1999) 424-431
77. Lisanti M.P., et al. Caveolae, transmembrane signalling and cellular transformation. Mol. Membr. Biol. 12 (1995) 121-124
78. Smart E.J., et al. Caveolins, liquid-ordered domains, and signal transduction. Mol. Cell. Biol. 19 (1999) 7289-7304
79. Schlegel A., and Lisanti M.P. The caveolin triad: caveolae biogenesis, cholesterol trafficking, and signal transduction. Cytokine Growth Factor Rev. 12 (2001) 41-51
80. Schlegel A., et al. Ligand-independent activation of oestrogen receptor alpha by caveolin-1. Biochem. J. 359 (2001) 203-210
81. Yang G., et al. Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res. 59 (1999) 5719-5723
82. Williams T.M., et al. Caveolin-1 promotes tumor progression in an autochthonous mouse model of prostate cancer: genetic ablation of Cav-1 delays advanced prostate tumor development in tramp mice. J. Biol. Chem. 280 (2005) 25134-25145
83. Parpal S., et al. Cholesterol depletion disrupts caveolae and insulin receptor signaling for metabolic control via insulin receptor substrate-1, but not for mitogen-activated protein kinase control. J. Biol. Chem. 276 (2001) 9670-9678
84. Peiro S., et al. PC12 cells have caveolae that contain TrkA. Caveolae-disrupting drugs inhibit nerve growth factor-induced, but not epidermal growth factor- induced, MAPK phosphorylation. J. Biol. Chem. 275 (2000) 37846-37852
85. Pike L.J., and Miller J.M. Cholesterol depletion delocalizes phosphatidylinositol bisphosphate and inhibits hormone-stimulated phosphatidylinositol turnover. J. Biol. Chem. 273 (1998) 22298-22304
86. Schnitzer J.E., et al. Filipin-sensitive caveolae-mediated transport in endothelium: reduced transcytosis, scavenger endocytosis, and capillary permeability of select macromolecules. J. Cell Biol. 127 (1994) 1217-1232
87. Williams T.M., et al. Stromal and epithelial caveolin-1 both confer a protective effect against mammary hyperplasia and tumorigenesis: caveolin-1 antagonizes cyclin D1 function in mammary epithelial cells. Am. J. Pathol. 169 (2006) 1784-1801
88. Sotgia F., et al. Caveolin-1, mammary stem cells, and estrogen-dependent breast cancers. Cancer Res. 66 (2006) 10647-10651
89. Sotgia F., et al. Caveolin-1 deficiency (-/-) conveys premalignant alterations in mammary epithelia, with abnormal lumen formation, growth factor independence, and cell invasiveness. Am. J. Pathol. 168 (2006) 292-309
90. Li T., et al. Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor alpha-positive status. Am. J. Pathol. 168 (2006) 1998-2013
91. Bouras T., et al. Caveolin-1 in breast cancer. Cancer Biol. Ther. 3 (2004) 931-941
92. Sloan E.K., et al. Caveolin-1 inhibits breast cancer growth and metastasis. Oncogene 23 (2004) 7893-7897
93. Zhuang L., et al. Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res. 62 (2002) 2227-2231
94. Wu X., et al. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 15587-15591
95. Adam R.M., et al. Cholesterol sensitivity of endogenous and myristoylated Akt. Cancer Res. 67 (2007) 6238-6246
96. Zhuang L., et al. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J. Clin. Invest. 115 (2005) 959-968
97. Istvan E.S., and Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292 (2001) 1160-1164
98. Platz et al. (2006) Association between plasma cholesterol and prostate cancer. AACR Frontiers in Cancer Prevention Research, Boston, MA, [abstract A179]